Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies at Delivery in Women, Partners, and Newborns
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
To investigate the frequency of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in parturient women, their partners, and their newborns and the association of such antibodies with obstetric and neonatal outcomes.
METHODS:
From April 4 to July 3, 2020, in a single university hospital in Denmark, all parturient women and their partners were invited to participate in the study, along with their newborns. Participating women and partners had a pharyngeal swab and a blood sample taken at admission; immediately after delivery, a blood sample was drawn from the umbilical cord. The swabs were analyzed for SARS-CoV-2 RNA by polymerase chain reaction, and the blood samples were analyzed for SARS-CoV-2 antibodies. Full medical history and obstetric and neonatal information were available.
RESULTS:
A total of 1,313 parturient women (72.5.% of all women admitted for delivery at the hospital in the study period), 1,188 partners, and 1,206 newborns participated in the study. The adjusted serologic prevalence was 2.6% in women and 3.5% in partners. Seventeen newborns had SARS-CoV-2 immunoglobulin G (IgG) antibodies, and none had immunoglobulin M antibodies. No associations between SARS-CoV-2 antibodies and obstetric or neonatal complications were found (eg, preterm birth, preeclampsia, cesarean delivery, Apgar score, low birth weight, umbilical arterial pH, need for continuous positive airway pressure, or neonatal admission), but statistical power to detect such differences was low. Full serologic data from 1,051 families showed an absolute risk of maternal infection of 39% if the partner had antibodies.
CONCLUSION:
We found no association between SARS-CoV-2 infection and obstetric or neonatal complications. Sixty-seven percent of newborns delivered by mothers with antibodies had SARS-CoV-2 IgG antibodies. A limitation of our study is that we lacked statistical power to detect small but potentially meaningful differences between those with and without evidence of infection.
Article activity feed
-
-
SciScore for 10.1101/2020.09.14.20191106: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable From April 4th, 2020 to July 3rd, 2020, (3 months), all women giving birth at the department, their partners and newborns were invited to participate in the study. Table 2: Resources
Antibodies Sentences Resources The serum from the blood samples from women, partners and newborns were analyzed for SARS-CoV-2 antibodies (IgM and IgG). SARS-CoV-2suggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: …SciScore for 10.1101/2020.09.14.20191106: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable From April 4th, 2020 to July 3rd, 2020, (3 months), all women giving birth at the department, their partners and newborns were invited to participate in the study. Table 2: Resources
Antibodies Sentences Resources The serum from the blood samples from women, partners and newborns were analyzed for SARS-CoV-2 antibodies (IgM and IgG). SARS-CoV-2suggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Strengths and limitations: Our study has several strengths. First, the present study is a comprehensive prospective cohort study from the largest obstetric department in Denmark including both parturient women, partners and newborns. Additionally, the health care system in Denmark is free of charge, which minimizes selection bias, and 95% of all births take place at a hospital. Secondly, we used serological testing, which is critical to investigate the association between previous COVID-19 disease and obstetric- and neonatal complications. Finally, we had complete data on obstetric- and neonatal outcomes from parturient women and their newborns in the study period, and all included women were pregnant when the novel virus spread worldwide, and we can thus conclude that the infection happened during pregnancy. In general, our study population was young with a median age of 31 years, had a normal BMI, were non-smokers and had had asymptomatic or mild COVID-19 disease without the need for hospitalization. Our results and conclusion may therefore not directly be applied to other populations with a higher BMI, higher frequency of smoking or severe COVID-19 infection. We used the iFlash 1800 with its IgM/IgG kit for serological testing, which has shown highly accurate results.16 A recent study has documented the sensitivity and specificity to be 42.0% and 99.7% for IgM and 94.0% and 99.3% for IgG, respectively.8 However, future studies are needed to validate the serological assays ...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
